Sepsis | Medical XPRT
Articles & Whitepapers
-
FDA Approved Peptide Drugs in the First Half of 2023
The FDA's Center for Drug Evaluation and Research (CDER) regulatory approval of a total of 26 NME (New Molecular Entity) drugs in the first half of 2023. It is worth noting that the 26 drugs approved include 4 peptide drugs, accounting for 15% of the total. In the past 2022, the FDA has approved only three peptide drugs: Tirzepatide, Lutetium 177Lu Vipivotide Tetraxetan and Terlipressin, of which ...
-
New Findings about Capsular polysaccharide You May Want to Know
Streptococcus pneumoniae is the leading cause of pneumonia, sepsis and meningitis. Collectively, these infections are a leading cause of morbidity and mortality in older adults and young children. To ...
News
-
Staphylococcus aureus and Mitigating Exposure Risks in Occupational, Healthcare and Community Settings
Frequently referred to as staph, Staphylococcus aureus is a type of bacteria that is commonly found on the skin and hair, as well as in the nose and throat of people and animals. In fact, the Centers for Disease Control and Prevention (CDC) reports ...
Protecting Patients, Workers and Building Occupants from Staphylococcus aureus and Other Pathogens in Puerto Rico
New partnership to advance glycoproteomics and biotherapeutics tools and research
Is data drift an issue for medical AI models - and what can we do about it?
CDRD Launches New Company Developing Life-Saving Sepsis Diagnostic
Equipment & Solutions
-
Showcase
Hospitals and Health Systems
VisualDx empowers clinicians with the tools they need to be more efficient and informed. More than 2,300 hospitals and healthcare institutions rely on VisualDx to improve diagnostic accuracy, enhance medical education, and engage patients in their treatment and care. Timely, accurate diagnoses reduce unnecessary treatments and admissions, improving overall outcomes.